Neuphoria Therapeutics Inc (NEUP) Stock Price, Quote & News

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 439 5551

Website: www.neuphoriatx.com

Address:

100 Summit Drive, Burlington, United States

joe77w Jul. 3 at 5:32 PM

$NEUP excellent job SKYROCKETS! I would add if reverse merger with SCANCELL to happen (AIM co. should pay in stock) the new NEUPHORIA called SCANCELL US Will have a TWO compounds/drugs in ph3 and ph2 with TAM worth billions and trials in late 2026/2027 with results in 2028. The close to enter in ph3 for which SCANCELL needs desperately money and NASDAQ listing therefore would buy Neuphoria by issuing stock, how much could get current NEUP owners in new Co? I have read some SCANCELL pps forecast if pipeline approved, could be worth billions and therefore NEUP current pps could be peanuts. Ok It Is speculation, but the reverse merger with SCANCELL if well enginereed and with favorable terms May give huge value to NEUP holders if pipeline finally approved and hit market. I would be glad to receive SCANCELL shares worth 25 mln USD in terms of current Neuphoria market cap because their pipeline well advanced.

1 · Reply

skyrockets_Inc Jul. 3 at 4:31 PM

$NEUP I asked AI to analyze the situation as of the most recent MK-1167 news. It gave a very clear, concise summary that almost 100% agrees w/ my separate analysis. Hope this is helpful for all invested.

3 · Reply

joe77w Jul. 3 at 12:51 PM

$NEUP stock going down in London below 15p, without some financing in short time SCANCELL may have issues. Lets hope both agree about Exchange ratio and other merger terms if any.

0 · Reply

specctham Jul. 3 at 8:03 AM

$NEUP They burn 50-70k per day, so give us the merger asap

0 · Reply

Quido22 Jul. 3 at 6:16 AM

$NEUP I was against reverse merger, but now it seems like the best option. Just end this suffering

0 · Reply

joe77w Jul. 2 at 5:34 PM

$NEUP I cannot believe the pipeline, the partnerships with Merck and Carina worth ZERO!?! THERE SHOULD BE SOME VALUE LEFT HERE! Otherwise pipeline should have been cancelled by website. Even assuming 1-2% recovery value of total royalties milestone etc 5 mln USD would be the minimum. Neuphoria does not spending for R&D, only G&A to retain NASDAQ listing and corporate officer hired plus investment Banks/advisors services. Nearly 1 mln USD should be easily achievable investing liquidity at high interest rates.

1 · Reply

joe77w Jul. 2 at 5:24 PM

$NEUP Neuphoria pipeline by website https://www.neuphoriatx.com/pipeline

0 · Reply

joe77w Jul. 2 at 4:59 PM

$NEUP SCLP 15 P in London, pps falling in last days. Market wants clarity about financing and RM therefore. Both companies urged by shareholders to find a deal.

0 · Reply

joe77w Jul. 2 at 4:57 PM

$NEUP worst case scenario ruling out liquidation (less than 3 USD per share imo), Just my opinion: 1) Cash 15 mln or 2.76 usd per share ; 2) NASDAQ listing 5 mln or .92 USD per share; 3) CNS IP whatever other clinical asset sold for 5 mln USD or .92 USD per share. The sum Is 4.60 USD per share.

0 · Reply

joe77w Jul. 2 at 4:53 PM

$NEUP https://www.biospace.com/drug-development/merck-axes-alzheimers-study-adding-to-partner-neuphorias-mounting-woes

0 · Reply

Neuphoria Therapeutics confirms merger discussions with Scancell Holdings

Jun 26, 2026, 4:15 PM EDT - 7 days ago

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

2026-05-15T18:23:29.000Z - 7 weeks ago

Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

May 15, 2026, 8:00 AM EDT - 7 weeks ago

Neuphoria Therapeutics Quarterly report: Q3 2026

Feb 17, 2026, 7:00 AM EST - 4 months ago

Neuphoria Therapeutics Quarterly report: Q2 2026

2025-12-08T13:05:17.000Z - 7 months ago

Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

Dec 8, 2025, 8:00 AM EST - 7 months ago

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Dec 8, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

2025-12-05T12:45:20.000Z - 7 months ago

Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

2025-12-04T13:10:52.000Z - 7 months ago

Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

Dec 4, 2025, 8:00 AM EST - 7 months ago

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Dec 4, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

2025-12-01T13:11:12.000Z - 7 months ago

Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1

Dec 1, 2025, 8:00 AM EST - 7 months ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Dec 1, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 25, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

2025-11-24T13:25:32.000Z - 7 months ago

Neuphoria Therapeutics urges stockholders to vote for company nominees

Nov 24, 2025, 8:00 AM EST - 7 months ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 24, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 24, 2025, 7:00 AM EST - 7 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 14, 2025, 7:00 AM EST - 8 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 14, 2025, 7:00 AM EST - 8 months ago

Neuphoria Therapeutics Quarterly report: Q1 2026

Nov 12, 2025, 7:00 AM EST - 8 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 12, 2025, 7:00 AM EST - 8 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Nov 11, 2025, 7:00 AM EST - 8 months ago

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Neuphoria Therapeutics Proxy statement: Proxy filing

Oct 27, 2025, 4:29 PM EDT - 8 months ago

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

2025-10-27T15:45:14.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

FUSE SMMT

2025-10-24T16:20:11.000Z - 9 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO

2025-10-23T17:05:21.000Z - 9 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO SMMT

2025-10-21T13:29:41.000Z - 9 months ago

Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?

2025-10-21T10:05:11.000Z - 9 months ago

Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital

2025-10-20T21:00:12.000Z - 9 months ago

Neuphoria Therapeutics Inc trading resumes

2025-10-20T20:50:24.000Z - 9 months ago

Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program

Oct 20, 2025, 4:15 PM EDT - 9 months ago

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

2025-10-20T20:10:11.000Z - 9 months ago

Neuphoria Therapeutics Inc trading halted, news pending

Sep 29, 2025, 4:54 PM EDT - 9 months ago

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Neuphoria Therapeutics Annual report: Q4 2025

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Neuphoria Therapeutics Earnings release: Q4 2025

Sep 4, 2025, 7:00 AM EDT - 10 months ago

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Aug 28, 2025, 4:05 PM EDT - 11 months ago

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:00 AM EDT - 11 months ago

Neuphoria Therapeutics Slides: Corporate presentation

May 27, 2025, 4:10 PM EDT - 1 year ago

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 20, 2025, 4:22 PM EDT - 1 year ago

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 8:00 AM EDT - 1 year ago

Neuphoria Therapeutics Quarterly report: Q3 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

Neuphoria Therapeutics Earnings release: Q3 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Mar 3, 2025, 7:30 AM EST - 1 year ago

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Feb 14, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Quarterly report: Q2 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Jan 24, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Registration statement: Registration filing

Jan 7, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Registration statement: Registration filing

Dec 23, 2024, 4:49 PM EST - 1 year ago

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

joe77w Jul. 3 at 5:32 PM

1 · Reply

skyrockets_Inc Jul. 3 at 4:31 PM

3 · Reply

joe77w Jul. 3 at 12:51 PM

$NEUP stock going down in London below 15p, without some financing in short time SCANCELL may have issues. Lets hope both agree about Exchange ratio and other merger terms if any.

0 · Reply

specctham Jul. 3 at 8:03 AM

$NEUP They burn 50-70k per day, so give us the merger asap

0 · Reply

Quido22 Jul. 3 at 6:16 AM

$NEUP I was against reverse merger, but now it seems like the best option. Just end this suffering

0 · Reply

joe77w Jul. 2 at 5:34 PM

1 · Reply

joe77w Jul. 2 at 5:24 PM

$NEUP Neuphoria pipeline by website https://www.neuphoriatx.com/pipeline

0 · Reply

joe77w Jul. 2 at 4:59 PM

$NEUP SCLP 15 P in London, pps falling in last days. Market wants clarity about financing and RM therefore. Both companies urged by shareholders to find a deal.

0 · Reply

joe77w Jul. 2 at 4:57 PM

0 · Reply

joe77w Jul. 2 at 4:53 PM

$NEUP https://www.biospace.com/drug-development/merck-axes-alzheimers-study-adding-to-partner-neuphorias-mounting-woes

0 · Reply

joe77w Jul. 2 at 4:52 PM

$NEUP" The other side: Neuphoria is facing difficulties. The US company launched a strategic review after its Phase III AFFIRM-1 study of BNC210 in social anxiety disorder missed its primary and secondary endpoints, prompting the company to halt development in that indication. Neuphoria is not just a shell. Its website still lists BNC210 for PTSD, several early-stage CNS programmes and a partnership with MSD covering two drug candidates in Alzheimer’s Disease and cognitive disorders. Scancell’s own statement frames the rationale around Nasdaq access and US investor visibility, not about acquiring a portfolio of CNS drugs."

0 · Reply

joe77w Jul. 2 at 4:51 PM

$NEUP https://european-biotechnology.com/latest-news/scancell-plots-reverse-merger-path-to-nasdaq/

0 · Reply

skyrockets_Inc Jul. 2 at 4:50 PM

$NEUP exactly. Similiar to my previous post. Read Lima's post below .

0 · Reply

joe77w Jul. 2 at 3:44 PM

$NEUP do you like to be the majority shareholder of a small co with minimal ops and cash or a minority One in a much big with a lot of cash and an excellent asset with market potential?

1 · Reply

joe77w Jul. 2 at 3:43 PM

$NEUP It Is not a SHELL but It May become without some ongoing compounds or agreements and then risk the delisting therefore RM earlier or later imo liquidation would destroy value imo https://www.otcmarkets.com/filing/html?id=19448765&guid=nCF-kqgiDmMNOth "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒"

0 · Reply

joe77w Jul. 2 at 2:44 PM

$NEUP I don't know, May be others on the tablet. SCANCELL good because It Is a ready to enter in ph3. Then who knows?

0 · Reply

I_am_retail_investor Jul. 2 at 2:43 PM

$NEUP - honestly don’t know how to trade this as a holder; does a RM with Scancell lead to dilution of existing retail shareholders for example.

1 · Reply

joe77w Jul. 2 at 2:40 PM

$NEUP $NEUP NEUP could for example give 2.5 USD in cash distribution per Share to shareholders and Lynx use this Money reveived to fund in part the buying of Bnc210, then this money again back to Neuphoria to do buyback and raise pps. A lot of ways to create value here imo.

2 · Reply

joe77w Jul. 2 at 2:38 PM

$NEUP $NEUP NASDAQ listing between 5 and 10 mln USD , cash well above 18 mln USD you Need to add recently 1 mln USD reveived in Australia, Fresh Money via Us listing I meant, without NASDAQ and Us Capital markets funding Will be Expensive. Neuphoria can stay years without marrying, SCANCELL needs right now otherwise It cannot start Ph3. Then Neuphoria Ip and pipeline has some Value imo. Neuphoria if sold for not than 5.25 USD imo.

1 · Reply

Biotech_Pharma_Investor Jul. 2 at 2:28 PM

$NEUP Scancell only need NASDAQ listing from $NEUP They need a PIPE to fund them. And it will be >>> than the $20M NEUP has (which is NOT a lot of money). Btw if Scancell pays NEUP $20M for the merger they get no cash. All that NEUP has to offer is the listing. Remove ongoing expenses and liabiliyies maybe $15M cash left after merger completes? Add $5M for nasdaq listing. Maybe $4 merger + CVR for Australian royalties And all above assuming that Scancell will find a decent PIPE for merger to make sense.

0 · Reply

joe77w Jul. 2 at 2:22 PM

$NEUP Is It SCANCELL desperately needing fresh Money or Neuphoria? The former not the latter One. Yes of course Neuphoria shareholders are not so Happy but they are not riskying bankruptcy! Neuphoria has a lot of cash and very low cash burn, no employees no debt so SCANCELL needs to offer very good terms, regardless of what happened Yesterday with Merck. Company does not deserve to be sold for 4/5 USD It would not be acceptable imo. CVRs are a must for whatever bidders.

0 · Reply

joe77w Jul. 2 at 2:09 PM

$NEUP https://www.biospace.com/drug-development/merck-axes-alzheimers-study-adding-to-partner-neuphorias-mounting-woes "That deal seems to have fizzled out after Lynx lowered its bid to $4.75 per share—a proposal that Neuphoria said in its news release “does not present an attractive value, and certainly not one that would compel the Board to consider abandoning its ongoing strategic review process.” Neuphoria is currently being courted by Scancell Holdings about a possible company combination, according to an announcement last week." Now CEO has the fiduciary duty to hand shareholders back at least 5.21 USD months After rejecting 5.2 USD offer by Lynx.

0 · Reply

Market Cap	18.27M
Revenue (ttm)	15.65M
Net Income (ttm)	-370,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.36%
Debt to Equity Ratio	0.00

Volume	118,700
Avg Vol	70,606
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	13%
Beta	0.74
Analysts	Hold
Price Target	$2.30